Improved Brain Uptake and Pharmacological Activity of Dalargin Using a Peptide-Vector-Mediated Strategy

  1. Christophe Rousselle,
  2. Philippe Clair,
  3. Maria Smirnova,
  4. Yuri Kolesnikov,
  5. Gavril W. Pasternak,
  6. Stéphanie Gac-Breton,
  7. Anthony R. Rees,
  8. Jean-Michel Scherrmann and
  9. Jamal Temsamani
  1. Synt:em, Parc Scientifique Georges Besse, Nîmes, France (C.R., P.C., M.S., S.G.B., A.R.R., J.T.); Department of Molecular Neuropharmacology, Memorial Sloan-Kettering Cancer Center, New York, New York (Y.K., G.W.P.); Institut National de la Santé et de la Recherche Médicale U26, Hôpital Fernand Widal, Paris, France (J.-M.S.)
  1. Address correspondence to:
    Jamal Temsamani, Synt:em, Parc Scientifique Georges BESSE, 30000 Nimes, France. E-mail: jtemsamani{at}syntem.com

Abstract

The blood-brain barrier restricts the passage of substances into the brain. Neuropeptides, such as enkephalins, cannot be delivered into the brain when given systemically because of this barrier. Therefore, there is a need to develop efficient transport systems to deliver these drugs to the brain. Recently, we have demonstrated that conjugation of doxorubicin or penicillin to peptide vectors significantly enhances their brain uptake. In this study, we have conjugated the enkephalin analog dalargin with two different peptide vectors, SynB1 and SynB3, to improve its brain delivery and its pharmacological effect. We show by in situ brain perfusion that vectorization markedly enhances the brain uptake of dalargin. We also show using the hot-plate model that this enhancement in brain uptake results in a significant improvement in the observed antinociceptive effect of dalargin. These results support the usefulness of peptide-mediated strategies for improving the availability and efficacy of central nervous system drugs.

Footnotes

  • DOI: 10.1124/jpet.102.048520.

  • ABBREVIATIONS: BBB, blood-brain barrier; DPDPE, [d-Pen2,d-Pen5]-enkephalin; P-gp, P-glycoprotein; CNS, central nervous system; HPLC, high-performance liquid chromatography; MALDI-TOF, matrix-assisted laser desorption-ionization time-of-flight mass spectrometry.

    • Received January 13, 2003.
    • Accepted April 3, 2003.
« Previous | Next Article »Table of Contents